

# COVID-19: Daily Update

26<sup>th</sup> March 2020


Brad Waddington, Economics & Markets Analyst, Longview Economics  
Email: [brad@longvieweconomics.com](mailto:brad@longvieweconomics.com)

*Below is a round-up of the latest developments relating to COVID-19. Given its potential for further significant impact on the global economy and markets, we have created this daily report with the intention of updating readers on key developments and themes relating to the virus. Feedback, as always, is appreciated.*

## Key Charts & News Flow

- Germany is testing around 500,000 people per week for the virus, according to a Berlin based virologist. He added that this high rate of testing is helping to prevent deaths (Germany's deaths remain one of the lowest in Europe). [RTRS](#)
- Spain has extended its lockdown by an additional 15 days (until 12<sup>th</sup> Apr). Originally, lockdown began on 14<sup>th</sup> Mar for 2 weeks. [RTRS](#)
- India announced a \$23bn bailout for the country's poorest citizens, providing food and direct cash transfers. [WSJ](#)
- Europe faces "severe constraints" in acquiring crucial drugs needed to fight coronavirus as shrinking global air freight capacity takes its toll, according to the continent's generic drugs industry board. [FT](#)

**Fig 1:** Daily changes in US & Spanish deaths due to COVID-19



Source: Longview Economics, Macrobond

## Table of Contents

|    |                                                                     |            |
|----|---------------------------------------------------------------------|------------|
| 1. | Summary of infections in major countries                            | p. 3 – 4   |
| 2. | Daily change in infections and deaths globally and in key countries | p. 5 – 10  |
| 3. | Summary of news flow on vaccines and treatments                     | p. 11      |
| 4. | Appendix A: Key Charts                                              | p. 12 – 16 |

## Key Charts & Tables


**Table 1:** Global COVID-19 testing statistics

| Country      | COVID-19 infections | Deaths due to COVID-19 | Tests performed           | Tests performed per mn people | % of tested that are infected | Infections per mn people | Date of reported testing stats |
|--------------|---------------------|------------------------|---------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------------|
| China        | 81,661              | 3,285                  | No testing data available |                               |                               | 58                       | N/A                            |
| Italy        | 74,386              | 7,503                  | 324,445                   | 5,386                         | 23%                           | 1,235                    | 25-Mar                         |
| US           | 65,778              | 942                    | 367,710                   | 1,116                         | 18%                           | 200                      | 26-Mar                         |
| Spain        | 49,515              | 3,647                  | 355,000                   | 7,537                         | 14%                           | 1,051                    | 23-Mar                         |
| Germany      | 37,323              | 206                    | No testing data available |                               |                               | 449                      | N/A                            |
| Iran         | 27,017              | 2,077                  | 80,000                    | 960                           | 34%                           | 324                      | 21-Mar                         |
| France       | 25,600              | 1,333                  | 101,046                   | 1,507                         | 25%                           | 382                      | 24-Mar                         |
| Switzerland  | 10,897              | 153                    | 50,000                    | 5,823                         | 22%                           | 1,269                    | 21-Mar                         |
| UK           | 9,640               | 466                    | 90,436                    | 1,361                         | 11%                           | 145                      | 24-Mar                         |
| Korea, South | 9,137               | 126                    | 364,942                   | 7,048                         | 3%                            | 176                      | 26-Mar                         |
| Netherlands  | 6,438               | 357                    | No testing data available |                               |                               | 369                      | N/A                            |
| Austria      | 5,588               | 30                     | 32,407                    | 3,640                         | 17%                           | 628                      | 25-Mar                         |
| Belgium      | 4,937               | 178                    | 18,360                    | 1,593                         | 27%                           | 428                      | 18-Mar                         |
| Canada       | 3,251               | 30                     | 142,154                   | 3,744                         | 2%                            | 86                       | 25-Mar                         |
| Norway       | 3,084               | 14                     | 73,089                    | 13,617                        | 4%                            | 575                      | 25-Mar                         |
| Portugal     | 2,995               | 43                     | 21,155                    | 2,059                         | 14%                           | 291                      | 23-Mar                         |
| Brazil       | 2,554               | 59                     | 45,708                    | 216                           | 6%                            | 12                       | 18-Mar                         |
| Israel       | 2,369               | 5                      | 32,346                    | 3,525                         | 7%                            | 258                      | 25-Mar                         |
| Australia    | 2,364               | 8                      | 180,047                   | 7,018                         | 1%                            | 92                       | 26-Mar                         |
| Denmark      | 1,862               | 34                     | 19,115                    | 3,283                         | 10%                           | 320                      | 26-Mar                         |
| Malaysia     | 1,796               | 20                     | 20,861                    | 637                           | 9%                            | 55                       | 25-Mar                         |
| Czechia      | 1,654               | 6                      | 26,698                    | 2,497                         | 6%                            | 155                      | 26-Mar                         |
| Ireland      | 1,564               | 9                      | 6,636                     | 1,348                         | 24%                           | 318                      | 17-Mar                         |
| Japan        | 1,307               | 45                     | 24,430                    | 194                           | 5%                            | 10                       | 24-Mar                         |
| Pakistan     | 1,063               | 8                      | 6,123                     | 28                            | 17%                           | 5                        | 25-Mar                         |
| Finland      | 880                 | 3                      | 10,000                    | 1,809                         | 9%                            | 159                      | 22-Mar                         |
| Indonesia    | 790                 | 58                     | 3,332                     | 12                            | 24%                           | 3                        | 25-Mar                         |
| Iceland      | 737                 | 2                      | 10,658                    | 29,259                        | 7%                            | 2,023                    | 24-Mar                         |
| Singapore    | 631                 | 2                      | 39,000                    | 6,838                         | 2%                            | 111                      | 25-Mar                         |

**Source:** Longview Economics, various official health organisations


## Top 10 infected countries

**Fig 2:** Confirmed COVID-19 cases in **top 10 infected countries**




Source: Longview Economics, Macrobond

**Fig 2a:** Infections in **top 10 infected countries** (timeline rebased to first 500 infections)




Source: Longview Economics, Macrobond

**Fig 3: Confirmed COVID-19 deaths in top 10 infected countries**




**Fig 3a: Deaths in top 10 infected countries (timeline rebased to first 10 deaths)**




## Global

**Fig 4:** Daily change in **global** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 4a:** Daily change in **global** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## China

**Fig 5:** Daily change in **Chinese** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 5a:** Daily change in **Chinese** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## South Korea

**Fig 6:** Daily change in **South Korean** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 6a:** Daily change in **South Korean** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## Italy

**Fig 7:** Daily change in **Italian** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond

**Fig 7a:** Daily change in **Italian** confirmed **deaths** from COVID-19




Source: Longview Economics, Macrobond




## Thailand

**Fig 8:** Daily change in **Thai** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 8a:** Daily change in **Thai** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## Iran

**Fig 9:** Daily change in **Iranian** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond

**Fig 9a:** Daily change in **Iranian** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond

## Vaccines: Latest news flow

---

26<sup>th</sup> Mar:

- Researchers have found that the virus is not mutating at a level that would make it significantly more deadly, raising hopes that vaccines (once developed) will be effective for most people.

**Source:** [The Hill](#)

25<sup>th</sup> Mar:

- No significant news flow.

24<sup>th</sup> Mar:

- Of around 35 companies and academic institutions racing to create a vaccine: One will enter human trials imminently; and four have candidates they have been testing in animals.

Some researchers doubt that a vaccine could be ready by the end of the year, though. “Like most vaccinologists, I don’t think this vaccine will be ready before 18 months,” says Annelies Wilder-Smith, professor of emerging infectious diseases at the London School of Hygiene and Tropical Medicine.

**Source:** [The Guardian](#)

- WHO Health Emergency Program Director, Mark Ryan, cautioned that a coronavirus vaccine will take another 12 – 18 months to become available for the public.

“I think we have to be realistic. Vaccines take a lot of time to develop, test, make them safe, prove they’re effective, then you need to produce enough vaccines for everybody,” Mike Ryan said.

**Source:** [The Hill](#)

## Treatments: Latest news flow

---

26<sup>th</sup> Mar:

- Drugmaker Gilead Sciences has asked the Food and Drug administration to rescind 'orphan status' for remdesivir, the company's experimental coronavirus treatment.

Gilead Sciences has come under heavy backlash following the designation, given that it allows the company to develop the drug without competition from other companies.

'Orphan drug' designation is intended to spur development of drugs for rare diseases by bestowing drugmakers with tax breaks, FDA fee waivers and seven years without generic competitors.

Gilead said it could proceed to develop the drug quickly without the special regulatory status.

**Source:** [NPR](#)

25<sup>th</sup> Mar:

- No significant news flow.

24<sup>th</sup> Mar:

- Gilead Sciences' experimental drug remdesivir, seen as one of the more promising potential treatments for the coronavirus, received the 'orphan drug' designation from the U.S. Food and Drug Administration.

The orphan drug status provides a seven-year market exclusivity period, as well as tax and other incentives for drug companies developing treatments for rare diseases that affect fewer than 200,000 people.

**Source:** [CNBC](#)

- New York health officials plan to begin collecting plasma from people who have recovered and injecting the antibody-rich fluid into patients still fighting the virus.


The treatment, known as convalescent plasma has some experts saying although somewhat primitive, might be the best hope for combating the coronavirus until more sophisticated therapies can be developed. The method is not without risks as there is danger in giving a patient the wrong type of blood or inadvertently transmitting other pathogens in a transfusion.

**Source:** [NBC News](#)

## Appendix A: Other Key Charts


### USA

**Fig 10:** Daily change in **US** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 10a:** Daily change in **US** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## Spain

**Fig 11:** Daily change in **Spanish** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 11a:** Daily change in **Spanish** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## Germany

**Fig 12:** Daily change in **German** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond


**Fig 12a:** Daily change in **German** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond


## France

**Fig 13:** Daily change in **French** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond

**Fig 13a:** Daily change in **French** confirmed **deaths** from COVID-19




Source: Longview Economics, Macrobond




## United Kingdom

**Fig 14:** Daily change in **UK** confirmed **cases** of COVID-19



Source: Longview Economics, Macrobond

**Fig 14a:** Daily change in **UK** confirmed **deaths** from COVID-19



Source: Longview Economics, Macrobond

This Publication is protected by U.K. and International Copyright laws.

All rights are reserved. No license is granted to the user except for the user's personal use. No part of this publication or its contents may be copied, downloaded, stored in a retrieval system, further transmitted, or otherwise reproduced, stored, disseminated, transferred, or used, in any form or by any means, except as permitted under agreement with Longview Economics Ltd.

This publication is proprietary and limited to the sole use of Longview Economics' clients and trial subscribers. Each reproduction of any part of this publication or its contents must contain notice of Longview Economics' copyright. This agreement shall be governed and construed in accordance with U.K. Copyright law and the parties hereto irrevocably submit to the exclusive jurisdiction of the English courts in respect of any dispute or matter arising out of or connected with this Agreement.

Any disclosure or use, distribution, dissemination or copying of any information received from Longview Economics Ltd. is strictly prohibited, whether derived from the reports or from any oral or written communication by way of opinion, advice, or otherwise with a principal of the company; and such information is not warranted in any manner whatsoever; and is for the use of our clients and trial subscribers only. Longview Economics Limited will not be liable for any claims or lawsuits from any third parties arising from the use or distribution of this document. This report is for distribution only under such circumstances as may be permitted by applicable law.

This publication is for your information only and is not intended as an offer, or a solicitation of an offer, to buy or sell any investment or other specific product. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. Certain services and products are subject to legal restrictions and cannot be offered worldwide on an unrestricted basis and/or may not be eligible for all investors. All information and opinions expressed in this document were obtained from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to the accuracy or completeness. All information and opinions as well as any prices indicated are current as of the date of this report, and are subject to change without notice. Some investments may not be readily realisable since the market in securities is illiquid and therefore valuing the investment and identifying the risk to which you are exposed may be difficult to quantify. Futures and options trading is considered risky. Past performance of an investment is no guarantee of its future performance. Some investments may be subject to sudden and large falls in values and on realisation you may receive back less than you invested or may be required to pay more. Changes in foreign exchange rates may have an adverse effect on the price, value or income of an investment. We are of necessity unable to take into account the particular investment objectives, financial situation and needs of our individual clients and we would recommend that you take financial and/or tax advice as to the implications (including tax) of investing in any of the products mentioned herein.

Longview Economics Ltd. is an appointed representative of Messels Limited. Messels Limited is authorised and regulated by the Financial Conduct Authority.